In bid to lower prices, Gottlieb says FDA will take new action to speed approval of biosimilars

(By Adam Feuerstein for STAT)

NEW YORK — Scott Gottlieb, the commissioner of the Food and Drug Administration, is a free-market proponent in a fervently anti-regulatory administration who is trying to lower drug prices by expanding the regulatory reach of the agency. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or


Leave a Reply